177 related articles for article (PubMed ID: 35780226)
1. An in situ hydrogel-mediated chemo-immunometabolic cancer therapy.
Wang B; Chen J; Caserto JS; Wang X; Ma M
Nat Commun; 2022 Jul; 13(1):3821. PubMed ID: 35780226
[TBL] [Abstract][Full Text] [Related]
2. Biomimetic Hydrogel-Mediated Mechano-Immunometabolic Therapy for Inhibition of ccRCC Recurrence After Surgery.
Dong Y; Luo J; Pei M; Liu S; Gao Y; Zhou H; Nueraihemaiti Y; Zhan X; Xie T; Yao X; Guan X; Xu Y
Adv Sci (Weinh); 2024 Jun; ():e2308734. PubMed ID: 38884220
[TBL] [Abstract][Full Text] [Related]
3. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism.
Yang Q; Hao J; Chi M; Wang Y; Xin B; Huang J; Lu J; Li J; Sun X; Li C; Huo Y; Zhang J; Han Y; Guo C
Oncoimmunology; 2022; 11(1):2055703. PubMed ID: 35355679
[TBL] [Abstract][Full Text] [Related]
4. Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect.
Cheng F; Su T; Zhou S; Liu X; Yang S; Lin S; Guo W; Zhu G
Sci Adv; 2023 Jul; 9(28):eade6257. PubMed ID: 37450588
[TBL] [Abstract][Full Text] [Related]
5. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Modulation of Kynurenine Based on Kynureninase-Loaded Nanoparticle Depot Overcomes Tumor Immune Evasion in Cancer Immunotherapy.
Chae SY; Shin H; Woo J; Kang S; Lee SM; Min DH
ACS Appl Mater Interfaces; 2024 Apr; 16(15):18490-18502. PubMed ID: 38573937
[TBL] [Abstract][Full Text] [Related]
7. Photothermal MnO
Chen Z; Zhang Q; Huang Q; Liu Z; Zeng L; Zhang L; Chen X; Song H; Zhang J
Int J Pharm; 2022 Apr; 617():121578. PubMed ID: 35176333
[TBL] [Abstract][Full Text] [Related]
8. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.
Wang H; Najibi AJ; Sobral MC; Seo BR; Lee JY; Wu D; Li AW; Verbeke CS; Mooney DJ
Nat Commun; 2020 Nov; 11(1):5696. PubMed ID: 33173046
[TBL] [Abstract][Full Text] [Related]
9. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity.
Liang J; Wang H; Ding W; Huang J; Zhou X; Wang H; Dong X; Li G; Chen E; Zhou F; Fan H; Xia J; Shen B; Cai D; Lan P; Jiang H; Ling J; Cheng Z; Liu X; Sun J
Sci Adv; 2020 Aug; 6(35):eabc3646. PubMed ID: 32923651
[TBL] [Abstract][Full Text] [Related]
11. Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment.
Huo W; Yang X; Wang B; Cao L; Fang Z; Li Z; Liu H; Liang XJ; Zhang J; Jin Y
Biomaterials; 2022 Sep; 288():121722. PubMed ID: 35963815
[TBL] [Abstract][Full Text] [Related]
12. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.
Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY
J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773
[TBL] [Abstract][Full Text] [Related]
13. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
[TBL] [Abstract][Full Text] [Related]
14. Injectable Anti-inflammatory Nanofiber Hydrogel to Achieve Systemic Immunotherapy Post Local Administration.
Chen M; Tan Y; Dong Z; Lu J; Han X; Jin Q; Zhu W; Shen J; Cheng L; Liu Z; Chen Q
Nano Lett; 2020 Sep; 20(9):6763-6773. PubMed ID: 32787149
[TBL] [Abstract][Full Text] [Related]
15. In situ gel implant for postsurgical wound management and extended chemoimmunotherapy against breast cancer recurrence.
Wang M; Wang S; Pan Y; Yu R; Zhang ZR; Fu Y
Acta Biomater; 2022 Jan; 138():168-181. PubMed ID: 34755605
[TBL] [Abstract][Full Text] [Related]
16. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
17. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
[TBL] [Abstract][Full Text] [Related]
18. Navoximod modulates local HSV-1 replication to reshape tumor immune microenvironment for enhanced immunotherapy via an injectable hydrogel.
Zhuang Q; Zhao B; Lin Z; Liang Y; Zhao Q; Wang Y; Liao N; Tu H; Zheng Y; Chen H; Zeng Y; Zhang D; Liu X
Commun Biol; 2023 Jun; 6(1):621. PubMed ID: 37296221
[TBL] [Abstract][Full Text] [Related]
19. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
20. Self-Splittable Transcytosis Nanoraspberry for NIR-II Photo-Immunometabolic Cancer Therapy in Deep Tumor Tissue.
Wang L; Jiang W; Su Y; Zhan M; Peng S; Liu H; Lu L
Adv Sci (Weinh); 2022 Nov; 9(32):e2204067. PubMed ID: 36073839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
